Interleukin-32 Gamma Specific Monoclonal Antibody and Developing IL-32 Specific ELISA

Cytokines are essential coordinators of defensive immune responses for resolving the invasion of pathogens such as bacteria, virus, and fungi. However, dysregulated cytokines are the main cause of various autoinflammatory immune disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Interleukin-32 (IL-32) is a recently described cytokine and characterized as a proinflammatory cytokine. IL-32 stimulates monocytes and macrophages to induce important proinflammatory cytokines (IL-1 beta, IL-6, and TNF alpha) and chemokines (IL-8 and MIP-2) by activating the NF-kappa B and p38 mitogen-activated protein (MAP) kinase pathways. The biological activities of IL-32 are associated with epidemic pathogens, Mycobacterium tuberculosis, influenza A virus, and human immunodeficiency virus (HIV). IL-32 is transcribed as six alternative splice variants (alpha, beta, gamma, delta, epsilon, and zeta), with IL-32 gamma being the most active isoform. However, it is unclear which isoform is related to specific disease activities since there are no high quality antibodies available to measure circulating IL-32 in biological samples of patients. Therefore, we developed specific anti-human IL-32 gamma monoclonal antibodies from recombinant human IL-32 gamma, which was expressed in Escherichia coli. The IL-32 gamma specific monoclonal antibodies recognized IL-32 in cell culture supernatants and serum of IL-32 gamma transgenic mice. The newly developed IL-32 gamma monoclonal antibodies will be a useful tool to measure IL-32 level in serum samples of various inflammatory diseases. These monoclonal antibodies will be helpful in investigating the precise function of IL-32 in immune responses and in autoinflammatory diseases.